80%Confidence
0Views
FDASource
2026-04-11Date
Summary
Apotex Corp's Class II recall for Brimonidine/Timolol eye drops over sterility issues affects a widely used glaucoma treatment, potentially causing supply disruptions. This may benefit competitors like Allergan if patients switch brands, but harm Apotex's market share.
Actionable: Explore competing ophthalmic solutions as alternatives and track Apotex's recall resolution timeline.
AI Confidence: 80%
Data Points
firmApotex Corp.
classificationClass II
statusOngoing
distributionU.S. Nationwide
productBrimonidine Tartrate/Timolol Maleate Ophthalmic Solution 0.2%/0.5%*, 5 mL, Rx Only, Sterile, Apotex Corp. Manufactured for: Apotex Corp., Weston, FL 3
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now